Crizanlizumab
Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
Trade Name | Adakveo |
---|---|
Common Name | Crizanlizumab |
Indication | sickle cell anemia |
Drug Class | Monoclonal antibodies: humanized, immunomodulating |
